BioSpace News Archive

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 135,900 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 324,200 shares of Arcutis’ common stock to 49 newly hired employees.

Xtant Medical Holdings, Inc. reported financial and operating results for the first quarter ended March 31, 2022.

Eyenovia, Inc. announced that the Company will release financial results for the first quarter ended March 31, 2022 on Thursday, May 12, 2022, after the markets close.

Neoleukin Therapeutics, Inc. announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), today presented new preclinical results demonstrating that STAT3 degradation alleviates Th17 inflammation and is active in a preclinical animal model of CNS inflammation, and that IRAK4 degradation blocks multiple innate immune signaling pathways across different immune cell types in a manner superior to kinase inhibitors.

Fulcrum Therapeutics, Inc.® announced that management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference, on Thursday, May 12, 2022 at 11:20 a.m. PT.

Flare Therapeutics today announced that Daphne Karydas, chief operating officer and chief financial officer will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Thursday, May 12th at 10:00 a.m. PT in Las Vegas, Nevada.

Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ultrasound, announced financial results for the quarter ended March 31, 2022, and provided a business update.

Metagenomi today announced that two presentations will be made at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtually and in Washington, D.C., May 16-19, 2022.

Palisade Bio and co-development partner Newsoara Biopharma Co. Ltd, today announced they have received clearance from the National Medical Products Administration (NMPA) in China to proceed with their Phase 3 clinical trial to evaluate LB1148 for accelerated return of bowel function in adult patients undergoing bowel/abdominal surgery.